openPR Logo
Press release

Ebola Vaccine Market Opportunity Analysis, 2018-2026

08-24-2018 03:27 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1365

Increasing number of Ebola cases in affected regions and new vaccine development for this are expected to be factors driving growth of the market

Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected African countries and people who came in contact with infected patients. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD.

According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company, was found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of fresh outbreak in vulnerable regions. Various key players are focusing on developing vaccines for EVD, in order to expand its market share. For instance, GlaxoSmithKline developed CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary recombinant technology.

In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.

Access Table of Content (TOC) Of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1365

GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ebola Vaccine Market Opportunity Analysis, 2018-2026 here

News-ID: 1200649 • Views: 238

More Releases from Coherent Market Insights

Virtual Data Room Market With Top Companies Ansarada, Brainloop virtual data roo …
North America is expected to be dominant in the global virtual data room market over the forecast period. Due to the massive growth in the business deals and transactions, such as mergers and acquisitions, joint ventures, and fundraising across the region due to the rapid expansion of SMEs (small and medium) enterprises as well as the higher development of infrastructure. 𝑻𝒉𝒆 𝒎𝒂𝒊𝒏 𝒌𝒆𝒚 𝒑𝒍𝒂𝒚𝒆𝒓𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒊𝒏𝒅𝒖𝒔𝒕𝒓𝒚 𝒂𝒓𝒆- Ansarada, Brainloop
Cloud Analytics Market With Top Companies Google, Vmware., Tibco, Teradata, Tabl …
The North America held a dominant position in the global cloud analytics market in 2016. Organisation shifting their workload in the cloud is one of the major driving factor for the growth of the market. According to the Coherent Market Insights analysis, in 2015, the cloud traffic was 1891 EB (Exabyte) and is estimated to reach 6844EB (Exabyte) by 2020. Therefore, with increase in cloud traffic requirement of analytics tools
Global Customer Relationship Management Market With Top Companies Oracle, SAP SE …
On the basis of geography, the global customer relationship management market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America held the dominant position in the market in 2016 and is projected to retain its dominance throughout the forecast period. The U.S. and Canada are some of the major growth engines in this region. 𝑻𝒉𝒆 𝒎𝒂𝒊𝒏 𝒌𝒆𝒚 𝒑𝒍𝒂𝒚𝒆𝒓𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒊𝒏𝒅𝒖𝒔𝒕𝒓𝒚 𝒂𝒓𝒆- Oracle Corporation,
Data Center Security Market With Top Companies Symantec, Juniper Networks, Alleg …
On basis of geography, the data center security market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to account for the largest share in the data center security market, due to high adoption of the cloud computing solutions and increasing number of data centers in the region. 𝑻𝒉𝒆 𝒎𝒂𝒊𝒏 𝒌𝒆𝒚 𝒑𝒍𝒂𝒚𝒆𝒓𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒊𝒏𝒅𝒖𝒔𝒕𝒓𝒚 𝒂𝒓𝒆- Symantec Corporation, Juniper Networks

All 5 Releases


More Releases for EVD

Ebola Vaccine Market Research By Leading Players Merck and Company, Janssen Phar …
In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells. According to study published in the journal, The Lancet,
Ebola Vaccine Market Analysis By Key Players Merck and Company, Janssen Pharmace …
In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells. Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/1365 According to study published in
Ebola Vaccine Market in Depth Analysis2026 | Top Key Players Merck and Company, …
In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells. According to study published in the journal, The Lancet,
Ebola Vaccine Market With The Global Market Scenario, Distinguishing Regions, An …
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus
Ebola Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunit …
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus
Ebola Vaccine Market - Global Industry Insights, and Opportunity Analysis, 2025
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus